Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 48.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,821 shares of the company's stock after selling 7,357 shares during the quarter. Gotham Asset Management LLC's holdings in Guardant Health were worth $239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd purchased a new position in Guardant Health during the fourth quarter worth $26,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health during the fourth quarter worth $43,000. Kimelman & Baird LLC purchased a new position in Guardant Health during the fourth quarter worth $58,000. NewEdge Advisors LLC boosted its stake in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Guardant Health during the fourth quarter worth $80,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 107,132 shares of company stock worth $5,248,393. 6.10% of the stock is owned by corporate insiders.

Guardant Health Stock Up 3.1%

Shares of GH stock traded up $1.17 on Tuesday, hitting $39.17. The stock had a trading volume of 1,826,979 shares, compared to its average volume of 2,143,862. The business has a 50 day moving average price of $43.11 and a 200 day moving average price of $40.30. The company has a market cap of $4.85 billion, a PE ratio of -11.00 and a beta of 1.49. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm's revenue was up 20.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.46) earnings per share. Equities research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GH shares. Guggenheim reaffirmed a "buy" rating and set a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. Morgan Stanley lifted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Raymond James reaffirmed an "outperform" rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Mizuho assumed coverage on shares of Guardant Health in a research note on Thursday, April 10th. They set an "outperform" rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group lifted their target price on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Guardant Health currently has an average rating of "Buy" and a consensus price target of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.